<DOC>
	<DOCNO>NCT02382640</DOCNO>
	<brief_summary>The purpose study assess effect antacid administration , time , bioavailability single dose febuxostat extended-release ( XR ) 80 mg .</brief_summary>
	<brief_title>Effect Antacid Bioavailability Febuxostat After Administration Febuxostat 80 mg Extended-Release Capsule</brief_title>
	<detailed_description>The drug test study call febuxostat extended-release ( XR ) . Febuxostat XR test assess antacid affect drug move throughout body . This study look lab safety side effect people take febuxostat XR . This cross-over study enroll approximately 36 patient . Participants randomly assign one four treatment sequence . All participant receive follow study medication end study : - Febuxostat XR 80 mg capsule - Maalox Advance Regular Strength liquid contain Aluminum Hydroxide 200 mg , Magnesium Hydroxide 200 mg , Simethicone 20 mg/5 mL equivalent All participant administer one dose one study medication Day 1 four separate study period . This single-centre trial conduct United States . The overall time participate study 84 day . Participants make 5 visit clinic include four 4-day period confinement clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , drug combination</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . Is healthy adult male female age 18 55 year , inclusive , checkin ( Day1 Period 1 ) 2 . Weighs least 50 kg ( 110 pound ) , body mass index ( BMI ) 18.0 kg/m^2 30 kg/m^2 , inclusive Screening . 3 . Has estimate glomerular filtration rate â‰¥90 mL/min Any participant meet follow criterion qualify entry study : 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Has receive febuxostat previous clinical study therapeutic agent . 3 . Has know hypersensitivity xanthine oxidase inhibitor , xanthine compound component formulation febuxostat tablet ( see Package Insert ) caffeine . 4 . Has know hypersensitivity aluminum , magnesium hydroxide , component formulation antacid ( Maalox Advanced Regular Strength equivalent ) ( see Package Insert ) . 5 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 6 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis frequent [ per week ] occurrence heartburn , surgical intervention [ eg , cholecystectomy ] ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>